Teemu J. Rintala

Teemu J. Rintala

Auto-generated profile, based on publicly available information

Teemu J. Rintala

Institute of Biomedicine University of Eastern Finland Kuopio Finland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
TRT J Rintala
T J Rintala
AGArindam Ghosh
Arindam Ghosh
VFVittorio Fortino
Vittorio Fortino
The network approach is quickly becoming a fundamental building block of computational methods aiming at elucidating the mechanism of action (MoA) and therapeutic effect of drugs. By modeling the effect of drugs and diseases on different biological networks, it is possible to better explain the interplay between disease perturbations and drug targets as well as how drug compounds induce favorable biological responses and/or adverse effects. Omics technologies have been extensively used to generate the data needed to study the mechanisms of action of drugs and diseases. These data are often exploited to define condition-specific networks and to study whether drugs can reverse disease perturbations. In this review, we describe network data mining algorithms that are commonly used to study drug’s MoA and to improve our understanding of the basis of chronic diseases. These methods can support fundamental stages of the drug development process, including the identification of putative drug targets, the in silico screening of drug compounds and drug combinations for the treatment of diseases. We also discuss recent studies using biological and omics-driven networks to search for possible repurposed FDA-approved drug treatments for SARS-CoV-2 infections (COVID-19).

14 October 2024 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Open access
Luca CattelaniLuca Cattelani
Luca Cattelani
AGArindam Ghosh
Arindam Ghosh
TRTeemu J. Rintala
Teemu J. Rintala
VFVittorio Fortino
Vittorio Fortino
Machine learning algorithms have been extensively used for accurate classification of cancer subtypes driven by gene expression-based biomarkers. However, biomarker models combining multiple gene expression signatures are often not reproducible in external validation datasets and their feature set size is often not optimized, jeopardizing their translatability into cost-effective clinical tools. We investigated how to solve the multi-objective problem of finding the best trade-offs between classification performance and set size applying seven algorithms for machine learning-driven feature subset selection and analyse how they perform in a benchmark with eight large-scale transcriptome datasets of cancer, covering both training and external validation sets. The benchmark includes evaluation metrics assessing the performance of the individual biomarkers and the solution sets, according to their accuracy, diversity, and stability of the composing genes. Moreover, a new evaluation metric for cross-validation studies is proposed that generalizes the hypervolume, which is commonly used to assess the performance of multi-objective optimization algorithms. Biomarkers exhibiting 0.8 of balanced accuracy on the external dataset for breast, kidney and ovarian cancer using respectively 4, 2 and 7 features, were obtained. Genetic algorithms often provided better performance than other considered algorithms, and the recently proposed NSGA2-CH and NSGA2-CHS were the best performing methods in most cases.

1 September 2024 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TRTeemu J Rintala
Teemu J Rintala
FNFerdinando Napolitano
Ferdinando Napolitano
VFVittorio Fortino
Vittorio Fortino
Cancer is a very heterogeneous disease that can be difficult to treat without addressing the specific mechanisms driving tumour progression in a given patient. High-throughput screening and sequencing data from cancer cell-lines has driven many developments in drug development, however, there are important aspects crucial to precision medicine that are often overlooked, namely the inherent differences between tumours in patients and the cell-lines used to model them in vitro. Recent developments in transfer learning methods for patient and cell-line data have shown progress in translating results from cell-lines to individual patients in silico. However, transfer learning can be forceful and there is a risk that clinically relevant patterns in the omics profiles of patients are lost in the process. We present MODAE, a novel deep learning algorithm to integrate omics profiles from cell-lines and patients for the purposes of exploring precision medicine opportunities. MODAE implements patient survival prediction as an additional task in a drug-sensitivity transfer learning schema and aims to balance autoencoding, domain adaptation, drug-sensitivity prediction, and survival prediction objectives in order to better preserve the heterogeneity between patients that is relevant to survival. While burdened with these additional tasks, MODAE performed on par with baseline survival models, but struggled in the drug-sensitivity prediction task. Nevertheless, these preliminary results were promising and show that MODAE provides a novel AI-based method for prioritizing drug treatments for high-risk patients. https://github.com/UEFBiomedicalInformaticsLab/MODAE.

5 August 2024 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
TRTeemu J. Rintala
Teemu J. Rintala
VFVittorio Fortino
Vittorio Fortino
Recent research on multi-view clustering algorithms for complex disease subtyping often overlooks aspects like clustering stability and critical assessment of prognostic relevance. Furthermore, current frameworks do not allow for a comparison between data-driven and pathway-driven clustering, highlighting a significant gap in the methodology. We present the COPS R-package, tailored for robust evaluation of single and multi-omics clustering results. COPS features advanced methods, including similarity networks, kernel-based approaches, dimensionality reduction, and pathway knowledge integration. Some of these methods are not accessible through R, and some correspond to new approaches proposed with COPS. Our framework was rigorously applied to multi-omics data across seven cancer types, including breast, prostate, and lung, utilizing mRNA, CNV, miRNA, and DNA methylation data. Unlike previous studies, our approach contrasts data- and knowledge-driven multi-view clustering methods and incorporates cross-fold validation for robustness. Clustering outcomes were assessed using the ARI score, survival analysis via Cox regression models including relevant covariates, and the stability of the results. While survival analysis and gold-standard agreement are standard metrics, they vary considerably across methods and datasets. Therefore, it is essential to assess multi-view clustering methods using multiple criteria, from cluster stability to prognostic relevance, and to provide ways of comparing these metrics simultaneously to select the optimal approach for disease subtype discovery in novel datasets. Emphasizing multi-objective evaluation, we applied the Pareto efficiency concept to gauge the equilibrium of evaluation metrics in each cancer case-study. Affinity Network Fusion, Integrative Non-negative Matrix Factorization, and Multiple Kernel K-Means with linear or Pathway Induced Kernels were the most stable and effective in discerning groups with significantly different survival outcomes in several case studies.

3 April 2020 in Health Research Policy and Systems
Verified
Journal Article
Open access
PDF file
JTJouni T. Tuomisto
Jouni T. Tuomisto
MPMikko Pohjola
Mikko Pohjola
TRTeemu J. Rintala
Teemu J. Rintala
Background: Evidence-informed decision-making and better use of scientific information in societal decisions has been an area of development for decades but is still topical. Decision support work can be viewed from the perspective of information collection, synthesis and flow between decision-makers, experts and stakeholders. Open policy practice is a coherent set of methods for such work. It has been developed and utilised mostly in Finnish and European contexts.Methods: An overview of open policy practice is given, and theoretical and practical properties are evaluated based on properties of good policy support. The evaluation is based on information from several assessments and research projects developing and applying open policy practice and the authors’ practical experiences. The methods are evaluated against their capability of producing quality of content, applicability and efficiency in policy support as well as how well they support close interaction among participants and understanding of each other’s views.Results: The evaluation revealed that methods and online tools work as expected, as demonstrated by the assessments and policy support processes conducted. The approach improves the availability of information and especially of relevant details. Experts are ambivalent about the acceptability of openness – it is an important scientific principle, but it goes against many current research and decision-making practices. However, co-creation and openness are megatrends that are changing science, decision-making and the society at large. Against many experts’ fears, open participation has not caused problems in performing high-quality assessments. On the contrary, a key challenge is to motivate and help more experts, decision-makers and citizens to participate and share their views. Many methods within open policy practice have also been widely used in other contexts.Conclusions: Open policy practice proved to be a useful and coherent set of methods. It guided policy processes toward a more collaborative approach, whose purpose was wider understanding rather than winning a debate. There is potential for merging open policy practice with other open science and open decision process tools. Active facilitation, community building and improving the user-friendliness of the tools were identified as key solutions for improving the usability of the method in the future.

5 October 2014 in Sustainability: Science, Practice and Policy
Verified
Journal Article
Open access
VSVilma Sandström
Vilma Sandström
JTJouni T. Tuomisto
Jouni T. Tuomisto
SMSami Majaniemi
Sami Majaniemi
TRTeemu Rintala
Teemu Rintala
MPMikko Pohjola
Mikko Pohjola
Biofuels have raised controversy regarding their environmental, social, and economic sustainability. The complexity of biofuel decisions and investments by both industry and society requires integration of scientific knowledge, public information, and values from a diversity of sources. Environmental assessments can identify multiple impacts of different options. Open and collaborative knowledge creation can support decisions in two ways: by building trust and credibility and by developing more robust understanding of key issues. Open assessment is a decision-support method that allows widespread participation in a transparent and freely accessible process. In this article, we evaluate two open assessment case studies concerning biodiesel production. The evaluation compiles the participants’ views regarding the potential of the assessment process to influence decisions in terms of quality of content, applicability, efficiency, and openness. According to the evaluation, openness can be feasibly implemented and is much appreciated by participants. More experience using broad and active participation is needed for further development of methods and tools. However, the currently common practices of closed and disengaged processes limit decision making. In addition, suitable tools and practices, as well as the inclusion of participants with appropriate skills, are needed to facilitate open collaboration.